Business
Eris Lifesciences Reports 11% YoY Growth In Domestic Formulations With Strong FY26 EBITDA Margin
Eris Lifesciences posted strong FY26 earnings with 11% growth in domestic formulations and a 37% EBITDA margin driven by diabetes and injectable portfolio expansion.
